4.7 Article

Genomic Landscape of CXCR4 Mutations in Waldenstrom Macroglobulinemia

期刊

CLINICAL CANCER RESEARCH
卷 22, 期 6, 页码 1480-1488

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-0646

关键词

-

类别

资金

  1. Comite Septentrion de la Ligue contre le Cancer et la Fondation Francaise pour la Recherche contre le Myelome et les Gammapathies (FFRMG)

向作者/读者索取更多资源

Purpose: Whole-genome sequencing has revealed MYD88 L265P and CXCR4 mutations (CXCR4(mut)) as the most prevalent somatic mutations in Waldenstrom macroglobulinemia. CXCR4 mutation has proved to be of critical importance in Waldenstrom macroglobulinemia, in part due to its role as a mechanism of resistance to several agents. We have therefore sought to unravel the different aspects of CXCR4 mutations in Waldenstrom macroglobulinemia. Experimental Design: We have scanned the two coding exons of CXCR4 in Waldenstrom macroglobulinemia using deep next-generation sequencing and Sanger sequencing in 98 patients with Waldenstrom macroglobulinemia and correlated with SNP array landscape and mutational spectrum of eight candidate genes involved in TLR, RAS, and BCR pathway in an integrative study. Results: We found all mutations to be heterozygous, somatic, and located in the C-terminal domain of CXCR4 in 25% of the Waldenstrom macroglobulinemia. CXCR4 mutations led to a truncated receptor protein associated with a higher expression of CXCR4. CXCR4 mutations pertain to the same clone as to MYD88 L265P mutations but were mutually exclusive to CD79A/CD79B mutations (BCR pathway). We identified a genomic signature in CXCR4(mut) Waldenstrom macroglobulinemia traducing a more complex genome. CXCR4 mutations were also associated with gain of chromosome 4, gain of Xq, and deletion 6q. Conclusions: Our study panned out new CXCR4 mutations in Waldenstrom macroglobulinemia and identified a specific signature associated to CXCR4(mut), characterized with complex genomic aberrations among MYD88L265P Waldenstrom macroglobulinemia. Our results suggest the existence of various genomic subgroups in Waldenstrom macroglobulinemia. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Rheumatology

Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis

Sebastien Sanges, Lisa Rice, Ly Tu, Eleanor Valenzi, Jean-Luc Cracowski, David Montani, Julio C. Mantero, Camille Ternynck, Guillemette Marot, Andreea M. Bujor, Eric Hachulla, David Launay, Marc Humbert, Christophe Guignabert, Robert Lafyatis

Summary: This study examined the serum proteome of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and identified two proteins that were significantly correlated with pulmonary vascular resistance (PVR), potentially providing biomarkers for earlier diagnosis and treatment.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Hematology

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures

Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M. Totiger, David Coffey, Namrata Chandhok, Justin Watts, Luisa Cimmino, Sydney X. Lu, Niccolo Bolli, Kelly Bolton, Heather Landau, Jae H. Park, Karuna Ganesh, Andrew McPherson, Mikkael A. Sekeres, Alexander Lesokhin, David J. Chung, Yanming Zhang, Caleb Ho, Mikhail Roshal, Jeffrey Tyner, Stephen Nimer, Elli Papaemmanuil, Saad Usmani, Gareth Morgan, Ola Landgren, Francesco Maura

Summary: Through genomic sequencing of 39 therapy-related myeloid malignancies, it was discovered that chemotherapy can accelerate the evolution of cancer cells by inducing mutations and DNA damage. Preleukemic clones (clonal hematopoiesis, CH) that exist before chemotherapy can acquire complex events and genomic drivers after chemotherapy, leading to the development of therapy-related myeloid neoplasms.
Article Oncology

ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies

Marion Perreard, Romane Florent, Jordane Divoux, Jean-Michel Grellard, Justine Lequesne, Melanie Briand, Benedicte Clarisse, Nathalie Rousseau, Esther Lebreton, Brice Dubois, Valentin Harter, Audrey Lasne-Cardon, Julien Drouet, Alisson Johnson, Anne-Laure Le Page, Celine Bazille, Corinne Jeanne, Martin Figeac, Nicolas Goardon, Dominique Vaur, Emmanuel Micault, Maxime Humbert, Juliette Thariat, Emmanuel Babin, Laurent Poulain, Louis-Bastien Weiswald, Vianney Bastit

Summary: This study aims to develop patient-derived tumor organoid (PDTO) models from Head and Neck Squamous Cell Carcinomas (HNSCC) in order to predict patients' response to treatment and evaluate innovative strategies. PDTO will be tested for sensitivity to chemotherapy, radiotherapy, and immunotherapy, and potential predictive biomarkers will be identified.

BMC CANCER (2023)

Editorial Material Hematology

Anti-PD-1 therapy can possibly reverse CAR T cells exhaustion in DLBCL

Sylvain Lamure, Charles Herbaux

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study

Guillaume Cartron, Emmanuel Bachy, Herve Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger

Summary: Rituximab improves progression-free survival and time to next treatment for patients with low-tumor burden follicular lymphoma. However, prolonged maintenance may raise concerns about resources use and patient adhesion. This study investigates the use of short rituximab maintenance using the subcutaneous route.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice

Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie-Jose Truong, Valerie Gregoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean-Pascal Meneboo, Sheherazade Sebda, Katia Bouchekioua-Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie-Christine Copin, David Tulasne, Alexis B. Cortot, Stephanie Kermorgant, Zoulika Kherrouche

Summary: Exon skipping mutations of the MET receptor tyrosine kinase (METex14) occur in a small percentage of non-small-cell lung cancer (NSCLC) and have been found to drive tumor growth and sensitivity to MET-tyrosine kinase inhibitors (TKIs). By using CRISPR/Cas9, researchers developed a METex14/WT isogenic model and demonstrated that the METex14 single alteration was sufficient to enhance cell survival and motility, as well as tumor formation, in vivo. They also found that human hepatocyte growth factor (hHGF) is required for the oncogenicity of METex14.

MOLECULAR ONCOLOGY (2023)

Letter Hematology

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group

Yassine Al Tabaa, Rene Oliver Casasnovas, Clio Baillet, Emmanuel Bachy, Emmanuelle Nicolas-Virelizier, Jean Marc Schiano De Colella, Clement Bailly, Salim Kanoun, Stephanie Guidez, Emmanuel Gyan, Remy Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Herve Tilly, Roch Houot, F. Morschhauser, Guillaume Cartron, Charles Herbaux

BLOOD ADVANCES (2023)

Article Hematology

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

Loic Vasseur, Laurene Fenwarth, Jerome Lambert, Stephane de Botton, Martin Figeac, Celine Villenet, Mael Heiblig, Pierre-Yves Dumas, Christian Recher, Celine Berthon, Emilie Lemasle, Delphine Lebon, Juliette Lambert, Christine Terre, Karine Celli-Lebras, Herve Dombret, Claude Preudhomme, Meyling Cheok, Raphael Itzykson, Nicolas Duployez

Summary: The expression of LSC17 gene is associated with risk stratification and measurable residual disease in AML patients, and high LSC17 expression is related to poor treatment response and shorter survival.

BLOOD ADVANCES (2023)

Article Oncology

The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

Jordane Divoux, Romane Florent, Margaux Jacobs, Justine Lequesne, Jean-Michel Grellard, Chankannira San, Sara Grossi, Katia Kerdja, Benedicte Clarisse, Gwenaelle Boudier, Francois Cherifi, Melanie Briand, Enora Dolivet, Alisson Johnson, Brice Dubois, Valentin Harter, Joelle Lacroix, Charlotte Raboutet, Brigitte Marie, Nathalie Rousseau, Cecile Blanc-Fournier, Dominique Vaur, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald, George Emile

Summary: This study aims to assess the feasibility of using patient-derived tumor organoids (PDTO) as predictive tools for evaluating the response of triple negative breast cancer (TNBC) patients to treatment. If PDTO can accurately predict patient response in a clinically relevant time frame, a prospective clinical trial could be designed to use PDTO to guide clinical decision-making. Additionally, this study will establish a living biobank of TNBC PDTO for future evaluation of innovative strategies.

BMC CANCER (2023)

Article Oncology

Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma

Eileen M. Boyle, Patrick Blaney, James H. Stoeckle, Yubao Wang, Hussein Ghamlouch, Dylan Gagler, Marc Braunstein, Louis Williams, Avital Tenenbaum, Ariel Siegel, Xiaoyi Chen, Gaurav Varma, Jason Avigan, Alexander Li, Monica Jinsi, David Kaminetzsky, Arnaldo Arbini, Lydia Montes, Jill Corre, Even H. Rustad, Ola Landgren, Francesco Maura, Brian A. Walker, Michael Bauer, Benedetto Bruno, Aristotelis Tsirigos, Faith E. Davies, Gareth J. Morgan

Summary: This study identified various molecular variants of chr1 and revealed their impact on pathway utilization. Whole-arm gains of 1q were found to be associated with complex genetics, adverse prognosis, and multiple key drivers, providing potential therapeutic targets.

CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site

Marie Fernandes, Sonia Paget, Zoulika Kherrouche, Marie-Jose Truong, Audrey Vinchent, Jean-Pascal Meneboo, Sheherazade Sebda, Elisabeth Werkmeister, Clotilde Descarpentries, Martin Figeac, Alexis B. Cortot, David Tulasne

Summary: MET exon 14 skipping and MET Y1003F mutation both contribute to cell transformation in lung cancer by activating downstream signaling pathways and increasing cell mobility.

FEBS LETTERS (2023)

Article Oncology

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Lucie Thorel, Pierre-Marie Morice, Hippolyte Paysant, Romane Florent, Guillaume Babin, Cecilia Thomine, Marion Perreard, Edwige Abeilard, Florence Giffard, Emilie Brotin, Christophe Denoyelle, Celine Villenet, Sheherazade Sebda, Melanie Briand, Florence Joly, Enora Dolivet, Didier Goux, Cecile Blanc-Fournier, Corinne Jeanne, Marie Villedieu, Matthieu Meryet-Figuiere, Martin Figeac, Laurent Poulain, Louis-Bastien Weiswald

Summary: In the era of personalized medicine, establishing preclinical models that faithfully recapitulate original tumors is crucial for guiding clinical decisions. This study established 7 models derived from the same Ovarian Clear Cell Carcinoma, and comprehensively characterized their morphological, histological, and transcriptomic features, as well as their response to treatment. The results showed that the PDX and PDTO models derived from the patient tumor were able to recapitulate tumor heterogeneity and resistance to conventional treatments, making them potential tools for therapeutic decision support.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Article Genetics & Heredity

The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation Hotspots

Gregory Lazarian, Bernard Leroy, Floriane Theves, Myriam Hormi, Remi Letestu, Virginie Eclache, Giulia Tueur, Adam Ameur, Audrey Bidet, Pascale Cornillet-Lefebvre, Frederic Davi, Eric Delabesse, Marie-Helene Estienne, Pascaline Etancelin, Olivier Kosmider, Sophy Laibe, Marc Muller, Nathalie Nadal, Dina Naguib, Cedric Pastoret, Stephanie Poulain, Pierre Sujobert, Lauren Veronese, Samia Imache, Valerie Lefebvre, Florence Cymbalista, Fanny Baran-Marszak, Thierry Soussi

Summary: TP53 aberrations are a major predictive factor for resistance to chemoimmunotherapy in CLL. This study analyzed 1,056 TP53 variants from 683 patients in France and compared them to a dataset of 5,173 TP53 variants from published articles. The analysis identified CLL-specific hotspot mutations and a novel splice variant. The study also found frequent copy-neutral loss of heterozygosity in CLL and the presence of multiple TP53 variants in a high proportion of patients.

HUMAN MUTATION (2023)

Article Immunology

Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis

Lea Fornero, Tarik Kanouni, Jean -Jacques Tudesq, Camille Pochard, Pauline Verot, Wendy Renier, Ludovic Gabellier, Guillaume Cartron, Philippe Guilpain, Charles Herbaux

Summary: The aim of this study is to evaluate the effectiveness of plasmapheresis initiated before or during rituximab treatment as prevention of cryoglobulinemic vasculitis flare. The results show that no flare occurred in the group receiving preventive plasmapheresis, while 5 flares occurred in the control group. Therefore, we believe that plasmapheresis is efficient and well tolerated to prevent rituximab-associated cryoglobulinemic vasculitis flare.

JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2023)

暂无数据